• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nevada Doctor Reports Cherie Thibodeau to Attorney General’s Office

Nevada Doctor Reports Cherie Thibodeau to Attorney General’s Office

November 26, 2007
CenterWatch Staff

Cherie Thibodeau, a fraudulent study broker, may not be working her scam much longer.

For the past few months, she has been trying to solicit Las Vegas area doctors for business, using a business card that says, “Cherie Thibodeau, M.D., PhD., Chief Medical Officer/Clinical Operations.” As far as can be determined, Cherie Thibodeau does not have a license to practice medicine, and posing as someone with a medical license is an offense that is under the jurisdiction of the Attorney General’s Office in Nevada.

One Nevada doctor, whose confidence Thibodeau gained, reported her to the Attorney General’s office last week.

Off and on between stints in California State Prison, Thibodeau has operated under several aliases, including Cherie Casio and Cherie Rivard, and last year, started claiming to have a medical degree. During the six years that CenterWatch has been reporting on her activities, Thibodeau has bilked numerous investigative sites across the U.S. out of potentially hundreds of thousands of dollars.

CenterWatch obtained a copy of a solicitation letter from an alert reader who recognized Thibodeau’s name from previous articles in CWWeekly and The CenterWatch Monthly. That letter was sent by “Cherie Thibodeau, M.D.” and “Dr. X” to Las Vegas area doctors on Oct. 3, 2007. The letter states that “Doctor X” has been selected to participate as a principal investigator in a phase IIa post-herpetic neuralgia clinical trial and is looking for “consulting physicians who are interested in referring patients who meet criteria for the study and enroll as possible participants.” Thibodeau promises compensation to doctors for patient referrals, which is unethical according to Good Clinical Practice.

Dr. X became suspicious of Thibodeau during the site review when she gave the monitor a different name  than the doctor knew her by—Cherie Casio. When Dr. X asked her about it, Thibodeau claimed that Casio was her maiden name and that she preferred to use it.

Thibodeau’s typical scam is to promise doctors that she will get them studies and handle administrative tasks for a percentage of the study budget. All payments go through her. Thibodeau starts off paying sites their fair share or enough of it for the first one or two studies and then pays them nothing and can’t be reached. Lately, she’s paid sites nothing at all, defrauding them of funds due them. Most recently, she bilked a site in Ohio out of $5,000.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing